Literature DB >> 19131478

Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests.

Rosa Burdi1, Jean-François Rolland, Bodvael Fraysse, Karina Litvinova, Anna Cozzoli, Viviana Giannuzzi, Antonella Liantonio, Giulia Maria Camerino, Valeriana Sblendorio, Roberta Francesca Capogrosso, Beniamino Palmieri, Francesca Andreetta, Paolo Confalonieri, Leonarda De Benedictis, Monica Montagnani, Annamaria De Luca.   

Abstract

The phosphodiesterases inhibitor pentoxifylline gained attention for Duchenne muscular dystrophy therapy for its claimed anti-inflammatory, antioxidant, and antifibrotic action. A recent finding also showed that pentoxifylline counteracts the abnormal overactivity of a voltage-independent calcium channel in myofibers of dystrophic mdx mice. The possible link between workload, altered calcium homeostasis, and oxidative stress pushed toward a more detailed investigation. Thus a 4- to 8-wk treatment with pentoxifylline (50 mg x kg(-1) x day(-1) ip) was performed in mdx mice, undergoing or not a chronic exercise on treadmill. In vivo, the treatment partially increased forelimb strength and enhanced resistance to treadmill running in exercised animals. Ex vivo, pentoxifylline restored the mechanical threshold, an electrophysiological index of calcium homeostasis, and reduced resting cytosolic calcium in extensor digitorum longus muscle fibers. Mn quenching and patch-clamp technique confirmed that this effect was paralleled by a drug-induced reduction of membrane permeability to calcium. The treatment also significantly enhanced isometric tetanic tension in mdx diaphragm. The plasma levels of creatine kinase and reactive oxygen species were both significantly reduced in treated-exercised animals. Dihydroethidium staining, used as an indicator of reactive oxygen species production, showed that pentoxifylline significantly reduced the exercise-induced increase in fluorescence in the mdx tibialis anterior muscle. A significant decrease in connective tissue area and profibrotic cytokine transforming growth factor-beta(1) was solely found in tibialis anterior muscle. In both diaphragm and gastrocnemius muscle, a significant increase in neural cell adhesion molecule-positive area was instead observed. This data supports the interest toward pentoxifylline and allows insight in the level of cross talk between pathogenetic events in workloaded dystrophic muscle.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131478     DOI: 10.1152/japplphysiol.90985.2008

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  35 in total

1.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

2.  Muscle damage, metabolism, and oxidative stress in mdx mice: Impact of aerobic running.

Authors:  Kevin E Schill; Alex R Altenberger; Jeovanna Lowe; Muthu Periasamy; Frederick A Villamena; JIll A Rafael-Fortney; Steven T Devor
Journal:  Muscle Nerve       Date:  2016-06       Impact factor: 3.217

3.  Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature.

Authors:  Maria A Potenza; Sara Gagliardi; Leonarda De Benedictis; Addolorata Zigrino; Edy Tiravanti; Giuseppe Colantuono; Antonio Federici; Loredana Lorusso; Vincenzo Benagiano; Michael J Quon; Monica Montagnani
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

Review 4.  Control of DNA integrity in skeletal muscle under physiological and pathological conditions.

Authors:  Yara Bou Saada; Vlada Zakharova; Boris Chernyak; Carla Dib; Gilles Carnac; Svetlana Dokudovskaya; Yegor S Vassetzky
Journal:  Cell Mol Life Sci       Date:  2017-04-25       Impact factor: 9.261

5.  Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice.

Authors:  Raffaella Willmann; Annamaria De Luca; Michael Benatar; Miranda Grounds; Judith Dubach; Jean-Marc Raymackers; Kanneboyina Nagaraju
Journal:  Neuromuscul Disord       Date:  2011-07-06       Impact factor: 4.296

6.  Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.

Authors:  Clara Sciorati; Roberta Buono; Emanuele Azzoni; Silvana Casati; Pierangela Ciuffreda; Grazia D'Angelo; Dario Cattaneo; Silvia Brunelli; Emilio Clementi
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  Consequences of MEGF10 deficiency on myoblast function and Notch1 interactions.

Authors:  Madhurima Saha; Satomi Mitsuhashi; Michael D Jones; Kelsey Manko; Hemakumar M Reddy; Christine C Bruels; Kyung-Ah Cho; Christina A Pacak; Isabelle Draper; Peter B Kang
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

9.  Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling.

Authors:  Genri Kawahara; Molly J Gasperini; Jennifer A Myers; Jeffrey J Widrick; Alal Eran; Peter R Serafini; Matthew S Alexander; Mathew T Pletcher; Carl A Morris; Louis M Kunkel
Journal:  Hum Mol Genet       Date:  2013-11-13       Impact factor: 6.150

10.  Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase.

Authors:  Anna Cozzoli; Antonella Liantonio; Elena Conte; Maria Cannone; Ada Maria Massari; Arcangela Giustino; Antonia Scaramuzzi; Sabata Pierno; Paola Mantuano; Roberta Francesca Capogrosso; Giulia Maria Camerino; Annamaria De Luca
Journal:  Am J Physiol Cell Physiol       Date:  2014-07-30       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.